Explore the latest projects funded through our funding platform that aims to speed up the translation of biomedical discoveries into commercially viable diagnostics, devices, therapeutics and tools to improve health and patient care.
A team of Rutgers researchers merged their ideas and technology with the support of research mentors to get the needed funds for developing a novel device capable of detecting the presence of viruses like SARS-CoV-2 in one’s breath.
Chlamydiae are common and important human pathogens. This HealthAdvance grant will apply a novel technology to develop a safe and effective life attenuated Chlamydia vaccine. Our vaccines will drastically reduce health and socioeconomic burdens of chlamydial diseases in women and men.
We have developed a novel, first-in-class GSX1 gene therapy that promotes the regeneration of spinal cord tissue, resulting in dramatic functional recovery in an animal model of spinal cord injury (SCI).
Many bacterial diseases are becoming more deadly as bacteria develop resistance to treatment with antibiotics. The proposed work describes an innovative path to identifying novel antibiotics.
Quantum Click is a software capable of formulating new drug candidates by screening billions of compounds virtually. Due to the exceptionally high accuracy, Quantum Click provides robust predictions of drug candidate-protein target interactions.
The long-term goal of this project is to develop a vaccine using centanamycin for DNA viruses where no drug or vaccine is available. Our study offers an attractive opportunity to develop chemically-attenuated live viruses as vaccines for the prevention and treatment of DNA viral infections.
One of the most critical hurdles to developing CRISPR-based therapies for genetic disorders is the lack of effective delivery systems. To this end, this project aims todevelop a next-generation CRISPR delivery solution for fast and effective genome editing that supports the need for the CRISPR-based drug development market.
The proposed technology will repair peripheral nerve injuries (PNI) by utilizing a biodegradable biopolymer scaffold enclosing a hydrogel-peptide matrix-based 3Dsystem combined with cultured autologous human cells to augment nerve growth once implanted.
We have engineered a bispecific killer cell engager (BiKE) that binds to CD16a receptors on the surface of natural killer (NK) cells with high affinity and specificity.
Tuberculosis is characterized by 10 million cases and 1.5 million deaths per year. New drugs are needed to reduce treatment duration and to treat drug-resistant infections. We propose a solution based on our preclinical drug lead (JSF-3285) that inhibits the essential ß-ketoacyl synthase and exhibits promising efficacy and safety profiles.